23612-36-4

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromo-5-azaindole is used as an intermediate in the synthesis of various pharmaceutical compounds for its potential biological properties. It contributes to the development of new drugs with therapeutic applications.
Used in Agrochemical Industry:
3-Bromo-5-azaindole is used as a building block in the development of new crop protection agents. Its potential biological properties make it a valuable component in creating effective and innovative agrochemical products.
Used in Anti-inflammatory Applications:
3-Bromo-5-azaindole is used as an anti-inflammatory agent due to its reported anti-inflammatory properties. It may contribute to the development of new treatments for inflammatory conditions by modulating inflammatory pathways and reducing inflammation.

InChI:InChI=1/C7H5BrN2/c8-6-4-10-7-1-2-9-3-5(6)7/h1-4,10H

Upstream product

• 271-34-1 5-azaindole 

Downstream Products

• 192189-29-0 2-(5-azaindol-3-yl)-5,11-dihydro-11-ethyl-5-methyl-6H-dipyrido[3,2-b;2',3'-e][1,4]diazepin-6-one 
• 192189-16-5 tert-butyl 3-bromo-1H-pyrrolo[3,2-c]pyridine-1-carboxylate 
• 1334711-83-9 1-{4-[3-(3,4-dichlorophenyl)-1H-pyrrolo[3,2-c]pyridin-1-yl]piperidin-1-yl}-2-hydroxyethan-1-one 
• 1334711-82-8 4-[3-(3,4-dichlorophenyl)-1H-pyrrolo[3,2-c]pyridin-1-yl]piperidine hydrochloride 
• 1334711-78-2 3-(4-chlorophenyl)-1-(oxan-4-yl)-1H-pyrrolo[3,2-c]pyridine 
• 1334711-77-1 3-(4-chlorophenyl)-1-(oxolan-3-yl)-1H-pyrrolo[3,2-c]pyridine 
• 1334712-93-4 tert-butyl 4-[3-(3,4-dichlorophenyl)-1H-pyrrolo[3,2-c]pyridin-1-yl]piperidine-1-carboxylate 
• 1334711-76-0 tert-butyl 4-[3-(4-chlorophenyl)-1H-pyrrolo[3,2-c]pyridin-1-yl]piperidine-1-carboxylate 
• 1334711-75-9 3-(4-chlorophenyl)-1-(oxolan-3-ylmethyl)-1H-pyrrolo[3,2-c]pyridine 
• 1334712-91-2 3-(4-chlorophenyl)-1H-pyrrolo[3,2-c]pyridine 
• 1334712-90-1 tert-butyl 3-(4-chlorophenyl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate 

Relevant academic research and scientific papers

Practical regioselective bromination of azaindoles and diazaindoles

A mild and efficient synthesis of various 3-brominated azaindoles and diazaindoles was developed by regioselective halogenation of the parent systems. This practical and high-yielding transformation was achieved with copper(II) bromide in acetonitrile at

PYRAZOLOPYRAZINE DERIVED COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USE THEREOF

Pyrazolopyrazine derived compounds as represented by general formulas (AI) and (I) or a pharmaceutically acceptable salt, a solvate, an active metabolite, a polymorph, an isotopic marker or an isomer thereof. Provided are a pharmaceutical composition comprising same and use of the compounds and the pharmaceutical composition in the preparation of medicaments for treating JAK kinase-mediated diseases. The compounds and pharmaceutical composition thereof provided have significant JAK kinase inhibitory activity, and in particular, have relatively high Tyk2 kinase inhibitory activity and selectivity for JAK2, and therefore have a very promising application potential.

TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF

Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, compositions, and mixtures thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing diseases (e.g., proliferative diseases (e.g., cancers, such as carcinoma, sarcoma, lung cancer, thyroid cancer, skin cancer, ovarian cancer, colorectal cancer, prostate cancer, pancreatic cancer, esophageal cancer, liver cancer, breast cancer)) in a subject. Provided are methods of inhibiting a TEAD transcription factors (e.g., TEAD1, TEAD2, TEAD3, TEAD4) in a subject.

New CRTh2 antagonists

The present invention relates to compounds of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.

NEW CRTH2 ANTAGONISTS

The present invention relates to compounds of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.

New Enzyme Inhibitor Compounds

Disclosed are compounds which inhibit SSAO enzyme activity. Also disclosed are pharmaceutical compositions comprising these compounds and the use of these compounds in the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases, immune disorders and the inhibition of tumour growth.

NEW ENZYME INHIBITOR COMPOUNDS

Compounds of formula (I) are inhibitors of Semicarbazide-sensitive amine oxidase wherein R1, A, X and R2 are as defined in the claims.

5-AZAINDOLE BISPHOSPHONATES

Novel 5-azaindole bisphosphonate compounds are disclosed, as well as methods of preparing the compounds, pharmaceutical compositions including the compounds, and administration of the compounds in methods of treating abnormal calcium and phosphate metabolism, including bone and joint diseases and other disorders.

Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. 6. 2-Indol-3-yl- and 2-azaindol-3-yl- dipyridodiazepinones

Modification of the non-nucleoside inhibitor of HIV-1 reverse transcriptase nevirapine (Viramune) by incorporation of a 2-indolyl substituent confers activity against several mutant forms of the enzyme.